Agios Pharmaceuticals (AGIO) Total Liabilities (2012 - 2026)

Agios Pharmaceuticals has reported Total Liabilities for 15 years, with the latest figure at $75.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 14.74% year-over-year to $75.9 million; the trailing twelve-month figure through Mar 2026 stood at $75.9 million (down 14.74% YoY), and the FY2025 full-year result was $104.1 million, down 14.83% from the prior year.
• Total Liabilities for Q1 2026 stood at $75.9 million, down from $104.1 million in the prior quarter.
• The five-year high for Total Liabilities was $165.1 million in Q3 2024, with the low at $75.9 million in Q1 2026.
• Historically, Total Liabilities has averaged $116.8 million across 5 years, with a median of $120.4 million in 2023.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 37.13% — and 2025, when it plunged 38.61%.
• Agios Pharmaceuticals' Total Liabilities stood at $137.9 million in 2022, then decreased by 8.56% to $126.1 million in 2023, then decreased by 3.06% to $122.2 million in 2024, then dropped by 14.83% to $104.1 million in 2025, then decreased by 27.12% to $75.9 million in 2026.
• The last three Total Liabilities figures came in at $75.9 million (Q1 2026), $104.1 million (Q4 2025), and $101.4 million (Q3 2025), per Business Quant data.